Careers

Browse our Current Job Openings:

Location: Doylestown, PA (On-site)

Position Overview:
As the Director of Research and Development, you will play a pivotal role in shaping the future of our company. You will lead a dedicated team of researchers and scientists to drive the continued development of our diagnostic products for the early detection of liver cancer through commercialization.

Key Responsibilities:

  • Lead and manage the R&D department to develop and execute a comprehensive R&D strategy focused on liver cancer diagnostics.
  • Oversee the development and validation of diagnostic products for liver cancer detection and other related assets.
  • Collaborate across departments to support clinical and commercialization efforts to bring products to market.
  • Establish and maintain relationships with key opinion leaders, vendors, and external research organizations.
  • Ensure that research projects are conducted within budget and meet project milestones in a timely manner.
  • Foster a culture of innovation, continuous learning, and scientific excellence within the R&D team.
  • Stay updated on industry trends, emerging technologies, and competitive landscape.

Qualifications:

  • Ph.D. in a relevant scientific discipline (e.g., Molecular Biology, Biochemistry, Pharmacology).
  • Minimum of 8 years of leadership experience in R&D within the biotechnology or pharmaceutical industry.
  • Strong experience with the development of IVDs, including both molecular-based tests and immunoassays, taking products from concept to commercial launch. Specific experience developing products related to the treatment and management of liver cancer is also desirable.
  • Understanding of regulatory requirements and compliance with relevant ISO, GLP, and GMP regulations in the biotechnology sector.
    Excellent communication skills and the ability to collaborate effectively with internal and external stakeholders.
  • Proven track record of successfully leading and managing R&D teams and projects.
  • Strategic thinker with a passion for making a meaningful impact in the field of liver cancer research.

We Offer:

  • Opportunity to lead cutting-edge research in liver cancer diagnostics and therapeutics.
  • Competitive salary and performance-based bonuses.
  • Comprehensive benefits package, including medical and 401k.
  • Stock options in growing early-stage biotechnology company.
  • Collaborative and inclusive work environment that fosters professional growth and development.
  • Chance to make a real difference in the lives of patients with liver cancer.

If you are a dynamic leader with a passion for advancing liver cancer research and diagnostics, we encourage you to apply for the position of Director of Research and Development at ImCare Biotech. Join us in our mission to transform the future of liver cancer care. Please submit your resume and a cover letter detailing your relevant experience and accomplishments.

ImCare Biotech is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

How to Apply:
Interested candidates are invited to submit their resume and cover letter to recruiting@imcarebiotech.com with the subject line “Director of Research and Development Application – [your name].”

Company News
12Apr
A review paper was published in the peer-reviewed journal Diagnostics, titled “Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)”. The paper analyzes the publicly available data on the LC-SPIK biomarker and its performance in detecting early stage liver cancer, […]
ImCare Biotech Team
(0)
(20059)
11Aug
A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 […]
ImCare Biotech Team
(0)
(66639)
29Oct
ImCare Biotech has been awarded a Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH).  This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal clinical study for FDA clearance of Seravue®, a diagnostic testing product for Hepatocellular Carcinoma (HCC). This follows the […]
ImCare Biotech Team
(0)
(76275)

There are currently no open positions available.

Company News
12Apr
A review paper was published in the peer-reviewed journal Diagnostics, titled “Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)”. The paper analyzes the publicly available data on the LC-SPIK biomarker and its performance in detecting early stage liver cancer, […]
ImCare Biotech Team
(0)
(20060)
11Aug
A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 […]
ImCare Biotech Team
(0)
(66640)
29Oct
ImCare Biotech has been awarded a Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH).  This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal clinical study for FDA clearance of Seravue®, a diagnostic testing product for Hepatocellular Carcinoma (HCC). This follows the […]
ImCare Biotech Team
(0)
(76276)